Managing cholesterol in patients with genetic predispositions has long relied on injectable therapies with compliance challenges. This development could transform treatment accessibility for the estimated 1 in 250 people worldwide carrying familial hypercholesterolemia mutations who struggle to reach target cholesterol levels despite maximum statin therapy.
The phase 3 trial demonstrated that enlicitide decanoate, an oral PCSK9 inhibitor, reduced LDL cholesterol by approximately 65% compared to placebo in 303 adults with heterozygous familial hypercholesterolemia across 59 international sites. Participants maintained their existing statin regimens while adding either 20mg daily enlicitide or placebo for 52 weeks. The compound targets the same PCSK9 pathway as established injectable medications like evolocumab and alirocumab but delivers the therapeutic effect through daily oral dosing rather than bi-weekly injections.
This represents a significant advancement in lipid management, particularly for patients with genetic cholesterol disorders who face lifetime cardiovascular risk. Current injectable PCSK9 inhibitors, while effective, present adherence barriers through complex administration requirements and substantial costs. An oral alternative could dramatically improve treatment persistence and expand access to this therapeutic class. However, several considerations temper immediate enthusiasm. The 52-week timeframe, while substantial for lipid trials, remains relatively brief for assessing long-term safety profiles of a novel oral mechanism. Additionally, the study focused specifically on familial hypercholesterolemia patients, leaving questions about broader applicability to standard hypercholesterolemia populations. The cardiovascular outcomes data, ultimately the most clinically relevant endpoint, will require longer follow-up studies to establish definitively.